Stocktoria
Alpha Cognition Inc. ACOG
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-06-09
Alpha Cognition Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $10.2M | — | — |
| R&D expense | $1.9M | $3.9M | $4.9M |
| SG&A expense | $29.1M | $8.0M | — |
| Operating income | -$22.7M | -$12.0M | -$9.9M |
| Net income | -$20.7M | -$14.8M | -$13.8M |
| EPS (diluted) | $-1.18 | $-2.04 | $-3.84 |
| Operating cash flow | -$20.4M | -$7.8M | -$8.8M |
| Free cash flow | -$20.7M | -$7.8M | — |
| Cash & equivalents | $66.0M | $48.5M | $1.4M |
| Inventory | $5.1M | $615,133 | — |
| Total assets | $79.7M | $50.7M | $2.5M |
| Total liabilities | $17.2M | $11.6M | $7.2M |
| Shareholders' equity | $62.5M | $39.1M | -$4.7M |
Source: SEC EDGAR filings · CIK 0001655923 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.